Biohaven Ltd
BHVN15.110USD
+1.750+13.10%
종가 07/17, 16:00（ET）시세는 15분 지연됩니다
1.54B시가총액
손실P/E TTM
자세한 내용은 Biohaven Ltd 회사
Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.
회사 정보
종목 코드 BHVN
회사 이름Biohaven Ltd
상장일Sep 23, 2022
설립일2022
CEODr. Vlad Coric, M.D.
직원 수256
유형Ordinary Share
회계 연도 종료Sep 23
주소215 Church Street
도시NEW HAVEN
증권 거래소NYSE Consolidated
국가United States of America
우편 번호06510
전화12034040410
웹사이트https://www.biohaven.com/
종목 코드 BHVN
상장일Sep 23, 2022
설립일2022
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
1.62M
--
Mr. Matthew (Matt) Buten
Mr. Matthew (Matt) Buten
Chief Financial Officer
Chief Financial Officer
193.45K
+0.39%
Dr. Bruce Car, Ph.D.
Dr. Bruce Car, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
34.80K
+757.19%
Ms. Julia Paige Gregory
Ms. Julia Paige Gregory
Independent Director
Independent Director
25.66K
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Lead Independent Director
Lead Independent Director
15.18K
--
Mr. Robert J. Hugin
Mr. Robert J. Hugin
Independent Director
Independent Director
12.96K
--
Dr. Irina Antonijevic, M.D., Ph.D.
Dr. Irina Antonijevic, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. John W. Childs
Mr. John W. Childs
Independent Director
Independent Director
--
--
Mr. Kishen (Kishan) Mehta
Mr. Kishen (Kishan) Mehta
Director
Director
--
--
Dr. Vlad Coric, M.D.
Dr. Vlad Coric, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
1.62M
--
Mr. Matthew (Matt) Buten
Mr. Matthew (Matt) Buten
Chief Financial Officer
Chief Financial Officer
193.45K
+0.39%
Dr. Bruce Car, Ph.D.
Dr. Bruce Car, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
34.80K
+757.19%
Ms. Julia Paige Gregory
Ms. Julia Paige Gregory
Independent Director
Independent Director
25.66K
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Lead Independent Director
Lead Independent Director
15.18K
--
Mr. Robert J. Hugin
Mr. Robert J. Hugin
Independent Director
Independent Director
12.96K
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Wed, May 14
마지막 업데이트: Wed, May 14
주주
주주 유형
주주
주주
비율
The Vanguard Group, Inc.
8.23%
1919 Investment Counsel, LLC
6.46%
Childs John W
6.38%
Janus Henderson Investors
6.30%
BlackRock Institutional Trust Company, N.A.
6.19%
Other
66.44%
주주
주주
비율
The Vanguard Group, Inc.
8.23%
1919 Investment Counsel, LLC
6.46%
Childs John W
6.38%
Janus Henderson Investors
6.30%
BlackRock Institutional Trust Company, N.A.
6.19%
Other
66.44%
주주 유형
주주
비율
Investment Advisor/Hedge Fund
37.06%
Investment Advisor
28.02%
Hedge Fund
18.28%
Individual Investor
11.53%
Private Equity
2.88%
Research Firm
2.07%
Sovereign Wealth Fund
0.88%
Bank and Trust
0.64%
Venture Capital
0.51%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
560
104.96M
102.79%
-7.46M
2025Q1
573
104.91M
102.74%
-8.33M
2024Q4
560
105.43M
103.87%
-2.30M
2024Q3
544
99.41M
101.90%
-4.10M
2024Q2
514
95.57M
103.25%
+3.60M
2024Q1
494
86.58M
104.39%
-3.45M
2023Q4
444
83.44M
104.38%
+4.72M
2023Q3
398
73.50M
107.61%
-2.29M
2023Q2
372
72.49M
106.13%
-7.40M
2023Q1
331
78.42M
114.97%
+3.79M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
The Vanguard Group, Inc.
8.40M
8.23%
+4.76K
+0.06%
Mar 31, 2025
1919 Investment Counsel, LLC
6.59M
6.46%
+34.44K
+0.53%
Mar 31, 2025
Childs John W
6.51M
6.38%
+351.58K
+5.71%
Mar 10, 2025
Janus Henderson Investors
6.44M
6.3%
-544.20K
-7.79%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.32M
6.19%
-61.68K
-0.97%
Mar 31, 2025
Suvretta Capital Management, LLC
5.62M
5.5%
--
--
Mar 31, 2025
Farallon Capital Management, L.L.C.
4.81M
4.71%
+385.00K
+8.69%
Mar 31, 2025
State Street Global Advisors (US)
3.42M
3.35%
-90.13K
-2.57%
Mar 31, 2025
Coric (Vladimir)
3.18M
3.11%
+26.57K
+0.84%
Mar 10, 2025
RP Management, LLC
2.94M
2.88%
--
--
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sun, Jul 6
마지막 업데이트: Sun, Jul 6
이름
비율
iShares Neuroscience and Healthcare ETF
2.32%
Roundhill GLP-1 & Weight Loss ETF
1.24%
Simplify Health Care ETF
1.16%
Global X Guru Index ETF
1.15%
Virtus LifeSci Biotech Clinical Trials ETF
0.85%
Tema Neuroscience and Mental Health ETF
0.56%
SPDR S&P Biotech ETF
0.45%
WisdomTree BioRevolution Fund
0.3%
Direxion Daily S&P Biotech Bull 3X Shares
0.26%
Main Thematic Innovation ETF
0.23%
더 보기
iShares Neuroscience and Healthcare ETF
비율2.32%
Roundhill GLP-1 & Weight Loss ETF
비율1.24%
Simplify Health Care ETF
비율1.16%
Global X Guru Index ETF
비율1.15%
Virtus LifeSci Biotech Clinical Trials ETF
비율0.85%
Tema Neuroscience and Mental Health ETF
비율0.56%
SPDR S&P Biotech ETF
비율0.45%
WisdomTree BioRevolution Fund
비율0.3%
Direxion Daily S&P Biotech Bull 3X Shares
비율0.26%
Main Thematic Innovation ETF
비율0.23%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
